Challenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the international society of liquid biopsy (ISLB)

dc.contributor.authorRolfo, Christian
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorCristofanilli, Massimo
dc.contributor.authorPaz-Ares, Luis
dc.contributor.authorDíaz-Mochõn, Juan José
dc.contributor.authorDurán, Ignacio
dc.contributor.authorRaez, Luis Estuardo
dc.contributor.authorRusso, Alessandro
dc.contributor.authorLorente, Jose A.
dc.contributor.authorMalapelle, Umberto
dc.contributor.authorGil-Bazo, Ignacio
dc.contributor.authorJantus Lewintre, Eloisa
dc.contributor.authorPauwels, Patrick
dc.contributor.authorMok, Tony
dc.contributor.authorSerrano, María José
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.date.accessioned2020-07-10T17:56:18Z
dc.date.available2020-07-10T17:56:18Z
dc.date.issued2020
dc.description.abstractenglishPrecision medicine was born with the development of new diagnostic techniques and targeted drugs, yielding better outcomes in cancer care. With the evolution and increasing sensitivity for detecting oncogenic drivers, liquid biopsies (LBs), specifically cell-free DNA (cfDNA) analysis, have been proposed as a minimally-invasive technique for genomic profiling. Ranging from sequencing techniques to PCR-based methods and other more complex strategies, this approach, currently applicable in some solid tumors with robust evidence, is showing promising opportunities in other cancers. However, difficulties in validating their clinical utility exist within limitation at different levels among several techniques, reporting of the results, lack of appropriate clinical trial designs, and unknown economic impact. One of the aims of the ISLB is to create recommendations to develop reliable and sustainable diagnostic, prognostic and predictive tools using LBs. This paper is addressing these objectives, helping the healthcare providers and scientific community to understand the potential of LB.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.critrevonc.2020.102978
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1040-8428
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3441
dc.language.isoeng
dc.publisher.journalCritical Reviews in Oncology/Hematologyspa
dc.relation.ispartofseriesCritical Reviews in Oncology/Hematology, 1040-8428, Vol. 151, 2020spa
dc.relation.urihttps://www.sciencedirect.com/science/article/abs/pii/S1040842820301165
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-04-29
dc.rights.localAcceso abiertospa
dc.subject.decsOncología médicaspa
dc.subject.decsNeoplasias pulmonaresspa
dc.subject.decsProcedimientos quirúrgicos mínimamente invasivosspa
dc.subject.keywordsLiquid biopsyspa
dc.subject.keywordsCell-free DNAspa
dc.subject.keywordsISLBspa
dc.titleChallenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the international society of liquid biopsy (ISLB)spa
dc.title.translatedChallenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the international society of liquid biopsy (ISLB)spa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Christian Rolfoa,_2020.pdf
Tamaño:
2.18 MB
Formato:
Adobe Portable Document Format
Descripción:
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:

Colecciones